Valuation: Prenetics Global Limited

Market Cap 279M 245M 226M 209M 396M 26.72B 404M 2.72B 1.06B 13.07B 1.05B 1.02B 45.38B P/E 2026 *
-6.32x
P/E 2027 * -27.6x
Enterprise Value 279M 245M 226M 209M 396M 26.72B 404M 2.72B 1.06B 13.07B 1.05B 1.02B 45.38B EV / Sales 2026 *
1.37x
EV / Sales 2027 * 0.87x
Free-Float
85.39%
Yield 2026 *
-
Yield 2027 * -
1 day-1.25%
1 week-7.32%
Current month-13.28%
1 month-17.10%
3 months-16.05%
6 months-1.01%
Current year+5.27%
1 week 15.91
Extreme 15.91
18.55
1 month 15.91
Extreme 15.91
22.22
Current year 14
Extreme 14
23.63
1 year 7.18
Extreme 7.175
23.63
3 years 2.85
Extreme 2.85
23.63
5 years 2.85
Extreme 2.85
131.25
10 years 2.85
Extreme 2.85
131.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 52 01/01/2014
Chief Executive Officer 47 01/01/2014
Director of Finance/CFO 41 01/01/2018
Director TitleAgeSince
Chairman 47 01/01/2014
Director/Board Member 38 -
Director/Board Member 60 13/06/2024
Date Insider Type Main position Quantity % Market Cap.
15/06Fiscal year

Director

15,625 0.1025%
15/06Fiscal year

Director

31,746 0.2082%
04/06Other

Director

24,004 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-1.25%-7.32%+104.44%+22.81% 279M
-0.69%+3.25%-28.63%-10.50% 166B
-2.17%+3.55%-7.42%-4.52% 105B
+1.67%+7.33%+3.87%+62.20% 60.23B
+2.11%-4.65%+41.65%+52.26% 49.17B
-3.67%-1.53%-13.78%-41.40% 41.49B
-6.30%-3.43% - - 34.08B
+0.67%+7.55%-11.58%-41.55% 28.58B
-0.67%-3.10%+60.41%-4.82% 24.99B
-2.57%+0.11%-10.62%+3.21% 20.64B
Average -1.30%+0.67%+15.37%+4.19% 53.02B
Weighted average by Cap. -1.06%+2.11%-5.70%+2.31%

Financials

2026 *2027 *
Net sales 203M 178M 164M 152M 288M 19.43B 294M 1.98B 768M 9.51B 762M 745M 33.01B 319M 280M 259M 239M 453M 30.57B 462M 3.11B 1.21B 14.96B 1.2B 1.17B 51.93B
Net income -48.71M -42.73M -39.45M -36.45M -69.09M -4.66B -70.47M -474M -184M -2.28B -183M -179M -7.92B -9.62M -8.44M -7.79M -7.2M -13.65M -921M -13.92M -93.66M -36.39M -451M -36.13M -35.34M -1.57B
Net Debt - -
Logo Prenetics Global Limited
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Employees
98
Date Price Change Volume
08/07/26 USD 16.58 -1.25% 171,041
07/07/26 USD 16.79 -4.00% 156,714
06/07/26 USD 17.49 +3.31% 140,958
02/07/26 USD 16.93 -5.37% 122,280
01/07/26 USD 17.89 -6.43% 65,868
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.58USD
Average target price
31.00USD
Spread / Average Target
+86.97%

Quarterly revenue - Rate of surprise